Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

In this article, we will take a look at 9 Oversold Biotech Stocks to Invest In. Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value ...

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

In this piece, we discuss the 10 Best Small-Cap Biotech Stocks to Buy According to Analysts. Small-cap biotech stocks are marking their latest resurgence, attracting renewed investor attention. This ...

The third-quarter 2025 reporting cycle of the Medical sector is currently approaching its end. The sector primarily comprises pharma/biotech and medical device companies. The Earnings Trends report ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...